1. Germany Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Bayer Aktiengesellschaft

Bayer Aktiengesellschaft

BAYN.SG
Bayer AktiengesellschaftDE flagStuttgart Stock Exchange
50.82
EUR
-2.32
- -
50.13BMarket Cap
Bayer Aktiengesellschaft
BAYN.SG
(Stuttgart Stock Exchange)

Recent

price

50.82

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
42.43
44.17
48.06
48.56
49.99
55.73
41.97
39.56
39.06
44.36
42.14
44.87
51.65
48.49
47.44
46.39
46.05
Revenue per Share
1.57
2.99
2.91
3.86
4.14
4.97
5.44
8.29
1.8
4.17
-10.68
1.02
4.22
-2.99
-2.6
-3.68
-2.19
Basic EPS, GAAP
5.15
4.17
3.15
3.64
4.16
5.29
7.82
6.52
5.66
5.66
2.53
2.52
4.22
2.41
4.67
3.5
2.69
Free Cash Flow per Basic Share
1.4
1.5
1.65
1.9
2.1
2.26
2.55
2.67
2.56
2.66
2.82
2.03
2.02
2.42
0.13
0.13
0.13
Dividend per Share
2.56
2.56
2.56
2.56
2.56
2.56
2.54
2.39
2.54
2.56
2.56
2.56
2.56
2.56
2.56
2.56
2.56
Book Value per Share
-1.53
-0.22
-0.25
2.45
-13.04
-7.05
2.42
11.79
-31.1
-27.08
-31.72
-33.79
-25.35
-22.99
-20.44
-23.02
-20.25
Tangible Book Value per Share
827
827
827
827
827
827
833
885
941
982
982
982
982
982
982
982
982
Basic Weighted Avg Shares
35,088
36,528
39,741
40,157
41,339
46,085
34,943
35,015
36,742
43,545
41,400
44,081
50,739
47,637
46,606
45,575
45,242
Sales/Revenue/Turnover
7.78
11.62
13.2
12.68
13.59
14.74
17.22
17.45
-0.5
10.82
-1.72
15.67
14.45
16.87
7.14
13.47
16.23
Operating Margin (%)
3,556
2,769
2,988
2,896
2,920
3,332
3,063
2,660
6,241
5,367
13,259
3,056
6,503
10,020
8,783
2,785
2,865
Depreciation Expense
1,301
2,470
2,403
3,189
3,426
4,110
4,531
7,336
1,695
4,091
-10,495
1,000
4,150
-2,941
-2,552
-3,620
-2,156
Net Income, GAAP
23.88
26.49
22.76
24.27
24.26
23.36
21.31
29.04
26.3
15.53
- -
50.05
10.79
- -
- -
- -
7.43
Effective Tax Rate (%)
3.71
6.76
6.05
7.94
8.29
8.92
12.97
20.95
4.61
9.39
-25.35
2.27
8.18
-6.17
-5.48
-7.94
-4.77
Profit Margin (%)
7,483
6,678
5,906
5,005
6,724
6,841
11,910
16,480
7,820
9,224
-1,093
3,175
2,676
8,099
5,492
326
1,841
Working Capital
9,582
7,686
6,706
5,044
17,797
16,332
15,375
12,158
37,708
36,907
33,198
36,478
33,781
38,170
35,491
31,806
- -
LT Debt
18,896
19,271
18,551
20,804
20,218
25,445
31,897
36,861
46,064
47,433
30,675
33,168
38,926
33,078
32,045
26,063
28,962
Total Equity
6.8
10.35
13.98
13.78
12.44
12.18
9.81
8.53
-0.2
4.57
- -
4.67
8.47
- -
- -
- -
- -
Return on Invested Capital (%)
9.4
24.69
25.66
37.72
26.69
22.58
22.41
38.55
9.65
13.29
- -
3.82
13.44
- -
- -
- -
25.88
Return on Capital (%)
61.45
116.67
113.51
150.64
161.83
194.14
214.03
346.53
75.27
166.91
-417.3
39.76
165.01
-116.94
-101.47
-143.94
-85.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
4,647
- -
LT Borrowings
- -
30,779
- -
LT Finance Leases
- -
1,027
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
982
982
982
Market Capitalization
27,685
36,340
39,041

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
32,881
32,911
35,301
Cash, Cash Equivalents & STI
7,242
7,856
6,660
Accounts Receivable, Net
9,988
9,077
12,907
Inventories
12,332
12,335
12,014
Total Current Liabilities
28,957
32,585
33,460
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,647
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.22%
-2.26%
-18.67%
Free Cash Flow
7.19%
18.61%
-24.99%
Net Income, GAAP
-15.67%
12.64%
41.85%
Sales/Revenue/Turnover
0.57%
2.22%
-2.21%
Total Cash Common Dividend
-6.48%
-21.22%
-3.05%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13,765
11,144
9,968
11,729
46,606
2025
13,738
10,739
9,660
11,438
45,575
2026
13,405
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.04
-0.03
-4.26
- -
-2.6
2025
1.32
-0.2
-0.98
- -
-3.68
2026
2.81
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.12
0.01
- -
0.13
2025
- -
0.11
0.01
- -
0.13
2026
- -
- -
- -
- -
- -
Similar Companies
SMS Pharmaceuticals Limited (SMSPHARMA.NS)
Biogen Inc. (IDP.DE)
Merck & Co., Inc. (MRK.PA)
Kopran Limited (KOPRAN.BO)
Biogen Inc. (BIIB.SW)
Bayer Aktiengesellschaft (BAYN.DE)
Business
Bayer AG (BAYN.SG) is a German multinational life sciences company focused on healthcare and agriculture. The company, founded in 1863 and headquartered in Leverkusen, Germany, operates through three main divisions: Pharmaceuticals, offering prescription medicines in cardiology, women's health, oncology, hematology, ophthalmology, and cell/gene therapies including products such as Xarelto (rivaroxaban), Eylea (aflibercept), Kerendia, Nubeqa, and the recently FDA-approved Lynkuet; Consumer Health, providing over-the-counter medicines, nutritional supplements, dermatology, pain relief, digestive health, allergy, cough/cold, and cardiovascular risk prevention solutions like Aspirin, Aleve, Berocca, and Redoxon; and Crop Science, delivering crop protection products (fungicides such as Nativo and Luna, herbicides like Liberty and Roundup, insecticides including Belt and Movento), seeds, traits, digital farming, fruits/vegetables, and environmental science. Bayer conducts global operations across Europe, North America, Latin America, Asia, and other regions, serving pharmaceutical customers, consumers, farmers, and agribusinesses. Recent developments include extension of the partnership with Ginkgo Bioworks in 2025 to advance microbial nitrogen fixation technologies reducing synthetic fertilizer needs; a 2025 deal with Kumquat Biosciences potentially worth $1.3 billion for a KRAS G12D inhibitor cancer drug candidate targeting pancreatic, colorectal, and lung cancers; expansion of regenerative agriculture collaboration with ADM in Hungary in 2025; FDA approval of Lynkuet for U.S. market entry in late 2025; plans for multiple blockbuster product launches in pharmaceuticals in 2025 such as Beyonttra and elinzanetant; and strengthened Crop Science growth with 22% corn sales increase driven by U.S. and Latin American expansions.